Dr. Cooperberg on Earlier Treatment With Sipuleucel-T

Matthew Cooperberg, MD, MPH
Published Online: Saturday, February 16, 2013
Matthew Cooperberg, MD, MPH, Assistant Professor of Urology; Epidemiology & Biostatistics, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses the earlier administration of treatment with sipuleucel-T (Provenge) for men with prostate cancer.

Cooperberg believes that immunotherapies, such as sipuleucel-T, are best administered earlier in the treatment paradigm when the immune system is stronger and less cancer cells are present.

To examine this, a study conducted at the University of California, San Francisco looked at the neoadjuvant administration of sipuleucel-T. The primary endpoints for this study were immune parameters that related to immune activation by sipuleucel-T. Cooperberg believes that from a mechanistic standpoint, sipuleucel-T may be most effective when given as a neoadjuvant therapy in prostate cancer.

<<< View coverage from the 2013 GU Cancers Symposium



Online CME Activities
Free CME from PER
Advances in Multiple Myeloma
Cancer Summaries and Commentaries™: Update from Chicago: Castrate Resistant Prostate Cancer and Advanced Melanoma
Community Practice Connections™: Novel Perspectives in Personalizing EGFR-Targeted Therapy in NSCLC: Frontline and Overcoming Resistance
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Gynecologic Cancers
More Reading
$auto_registration$